OPK Volume Alert - OPK 8.60 Opko Health Inc $OPK Hit a high of 8.63 Currently 11:15 Last price 8.60 +0.28 +3.37% With a day low of 8.30 and a current volume of 2,256,608.
OPK Opko Health Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.28 (+1.84), LLY: 67.97 (+1.37), CNCE: 13.67 (+0.57), OPK: 8.58 (+0.26), AZN: 73.29 (+0.41), ALXN: 194.09 (+0.28), ICPT: 179.06 (+6.47), NPSP: 26.90 (-0.59), XLRN: 31.63 (+1.44)
OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore(TM) Test for High Grade Prostate Cancer in the United States
Business Wire - Mon Nov 10, 7:37AM CST
OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a multi-institutional, prospective study of the 4Kscore Test in the journal European Urology. The results of the study demonstrated that the 4Kscore provides a patient with accurate and personalized information about their risk of having Gleason Score greater-than or equal to7 prostate cancer, making it a useful tool for selecting men who have significant disease and are most likely to benefit from a prostate biopsy.
OPK: 8.58 (+0.26)
'Mad Money' Lightning Round: I'm Going Nowhere Near Sony
at The Street - Sat Nov 08, 5:00AM CST
Cramer likes Skyworks Solutions over Micron, Kinder Morgan over Buckeye Partners and thinks SeaDrill is a house of pain.
KMI: 38.57 (-0.18), MU: 32.99 (-0.02), LMT: 186.81 (+0.66), SWKS: 61.19 (+1.31), OPK: 8.58 (+0.26), TXN: 51.51 (+0.61), QCOM: 69.91 (+0.65), BPL: 79.62 (+0.32), AVAV: 29.12 (-0.69), IRM: 37.45 (-0.60), SNE: 20.53 (+0.91), SDRL: 21.85 (+0.08)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.63 (+0.50), KMI: 38.57 (-0.18), HK: 3.23 (-0.01), KSS: 56.86 (-0.36), GE: 26.47 (+0.06), LMT: 186.81 (+0.66), AVAV: 29.12 (-0.69), WMT: 80.05 (+1.28), SNE: 20.53 (+0.91), M: 59.58 (-0.30), SDRL: 21.85 (+0.08), T: 35.08 (+0.17), W: 26.43 (+0.42), OPK: 8.58 (+0.26), QCOM: 69.91 (+0.65), TWTR: 40.03 (-0.28), EPR: 57.59 (+0.98), AAPL: 108.98 (-0.03), HSIC: 129.36 (+0.52), CSCO: 25.20 (-0.13), WFM: 47.80 (+0.99), CY: 10.17 (+0.09), MU: 32.99 (-0.02), SWKS: 61.19 (+1.31), IRM: 37.45 (-0.60), BAC: 17.35 (-0.01), MO: 49.98 (+0.11), CSX: 36.38 (+0.93), WWAV: 35.80 (-1.13), GILD: 107.18 (+0.73), TXN: 51.51 (+0.61), BPL: 79.62 (+0.32), JCP: 7.37 (-0.45), JWN: 72.46 (-0.97), BABA: 117.47 (+2.91)
OPKO To Hold Conference Call on November 10, 2014
Business Wire - Fri Nov 07, 10:31AM CST
OPKO Health, Inc. (NYSE:OPK) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014, before the market opens. OPKO's senior management team will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, November 10, 2014 to discuss the Company's results in greater detail.
OPK: 8.58 (+0.26)
OPKO Health misses 3Q revenue forecasts
Automated Insights - Fri Nov 07, 7:45AM CST
MIAMI (AP) _ Opko Health Inc. (OPK) on Friday reported a loss of $48.7 million, or 11 cents per share, in its third quarter.
OPK: 8.58 (+0.26)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.22 (+0.06), OPK: 8.58 (+0.26), VNDA: 12.04 (+0.25), MDXG: 10.01 (-0.23), PDLI: 7.79 (-0.19)
OPKO Announces Third Quarter Operating and Financial Results
Business Wire - Fri Nov 07, 7:28AM CST
--Rayaldee Results to be Presented at American Society of Nephrologists Meeting
OPK: 8.58 (+0.26)
DSG and OPKO Health Enter into Enterprise Licensing Agreement for Fully Integrated EDC, IWRS, Safety, and Trial Management Solution
Business Wire - Tue Nov 04, 9:14AM CST
OPKO Health, Inc., a multinational pharmaceutical & diagnostics company, has selected DSG's eCaseLink integrated suite for self-building of harmonized electronic data capture (EDC), IWRS, drug safety event capture and case reporting, and CTMS systems. DSG's team will support the OPKO team and their Site users 24 x 365.
OPK: 8.58 (+0.26)
Insider Trading Recap for Alpha Pro Tech, Opko Health, Yelp, Glu Mobile, Lakeland Industries, and Plug Power
PR Newswire - Fri Oct 31, 7:45AM CDT
Insiderslab.com, an US market research community has a special focus on updating investors with insider trading news, reveals the latest insider trading alerts for the US stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Alpha Pro Tech (NYSEMKT:APT), Opko Health (NYSE:OPK), Yelp (NYSE:YELP), Glu Mobile (NASDAQ:GLUU), Lakeland Industries (NASDAQ:LAKE), and Plug Power (NASDAQ
LUG).
OPK: 8.58 (+0.26), PLUG: 5.24 (-0.06), APT: 3.26 (unch), LAKE: 13.18 (-0.11), GLUU: 3.77 (+0.06), YELP: 59.16 (+0.75)
5 Stocks Insiders Love Right Now
at The Street - Wed Oct 29, 12:00PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
AGO: 24.71 (+0.18), OPK: 8.58 (+0.26), JONE: 13.15 (-0.39), SHLD: 39.62 (-3.19), SLB: 98.93 (+0.20)
Investments Gamma. Frost Trust of Opko Health, Inc. (OPK)-NYSE bought Shares of OPK
M2 - Fri Oct 24, 7:57AM CDT
Reported by InsiderCow.com at 2014-10-23 08:00:05 ET
OPK: 8.58 (+0.26)
Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 8.58 (+0.26)
Critical Alerts For Boston Beer, Apollo Group, Opko Health, Vale and Silver Wheaton Released By InvestorsObserver
PR Newswire - Mon Oct 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SAM, APOL, OPK, VALE and SLW.
OPK: 8.58 (+0.26), VALE: 9.20 (-0.23), SLW: 18.11 (-0.75), SAM: 264.07 (+5.17), APOL: 28.98 (-0.46)
'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin
at The Street - Thu Oct 16, 5:00AM CDT
Cramer says be careful about Compressco Partners, buy RPM International and consider Rite Aid a great long-term story.
LMT: 186.81 (+0.66), LEN: 45.72 (+1.18), OPK: 8.58 (+0.26), GWPH: 73.33 (-0.64), RPM: 46.51 (+0.10), GSJK: 22.74 (-0.42), RAD: 5.49 (+0.08)
Jim Cramer's 'Mad Money' Recap: More Nails in the Market's Coffin
at The Street - Wed Oct 15, 7:28PM CDT
The markets will continue to be driven by news, with stocks being guilty until proven innocent, Cramer warns.
LMT: 186.81 (+0.66), LEN: 45.72 (+1.18), CLR: 55.69 (+0.56), OPK: 8.58 (+0.26), GWPH: 73.33 (-0.64), SHPG: 200.52 (+1.94), LNG: 72.46 (+0.51), WMT: 80.05 (+1.28), RPM: 46.51 (+0.10), FRT: 134.26 (+1.36), ABBV: 63.54 (+2.04), GSJK: 22.74 (-0.42), RAD: 5.49 (+0.08), CRM: 64.12 (+0.15)
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the Tiara(TM) Transcatheter Mitral Valve
Business Wire - Thu Oct 09, 10:15AM CDT
OPKO Health, Inc. (NYSE:OPK) announced that its investee, Neovasc, has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara(TM) transcatheter mitral valve. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted to assess the safety and performance of Neovasc's Tiara mitral valve system and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).
OPK: 8.58 (+0.26)
Masimo Gets CE Mark Approval for 11th Rainbow Parameter - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 12:50PM CDT
Masimo Corporation's (MASI) Oxygen Reserve Index (ORI) is the first non-invasive and continuous parameter of its kind which provides an insight into patients' oxygen reserve when they are receiving supplemental oxygen.
GE: 26.47 (+0.06), MASI: 25.60 (+0.08), OPK: 8.58 (+0.26), ERB: 2.75 (-0.37)
Mazor Robotics Ltd. (MZOR) in Focus: Stock Soars 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 8:18AM CDT
Mazor Robotics Ltd. (MZOR) was a big mover last session, as the company saw its shares rise by over 11% on the day.
OPK: 8.58 (+0.26), MZOR: 10.43 (-0.51), ERB: 2.75 (-0.37)
Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences
PR Newswire - Tue Sep 30, 7:50AM CDT
Investor-Edge has initiated coverage on the following equities: Immunomedics Inc. (NASDAQ: IMMU), Aeterna Zentaris Inc. (NASDAQ: AEZS), OPKO Health Inc. (NYSE: OPK), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, September 29, 2014, the NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow Jones Industrial Average finished the day 0.25% lower at 17,071.22, and the S&P 500 closed at 1,977.80, down 0.25%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 744.38, down 0.18%, while the index has advanced 0.92% in the last one month. Register for your complimentary reports on these five stocks at:
IMMU: 3.66 (+0.05), NAVB: 1.04 (-0.18), OPK: 8.58 (+0.26), AEZS: 0.59 (+0.02), EXAS: 22.34 (-0.48)
OPK Opko Health Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.28 (+1.84), LLY: 67.97 (+1.37), CNCE: 13.67 (+0.57), OPK: 8.58 (+0.26), AZN: 73.29 (+0.41), ALXN: 194.09 (+0.28), ICPT: 179.06 (+6.47), NPSP: 26.90 (-0.59), XLRN: 31.63 (+1.44)
OPKO Announces Publication of Large, Prospective, Multi-Institutional Clinical Validation of the 4Kscore(TM) Test for High Grade Prostate Cancer in the United States
Business Wire - Mon Nov 10, 7:37AM CST
OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a multi-institutional, prospective study of the 4Kscore Test in the journal European Urology. The results of the study demonstrated that the 4Kscore provides a patient with accurate and personalized information about their risk of having Gleason Score greater-than or equal to7 prostate cancer, making it a useful tool for selecting men who have significant disease and are most likely to benefit from a prostate biopsy.
OPK: 8.58 (+0.26)
'Mad Money' Lightning Round: I'm Going Nowhere Near Sony
at The Street - Sat Nov 08, 5:00AM CST
Cramer likes Skyworks Solutions over Micron, Kinder Morgan over Buckeye Partners and thinks SeaDrill is a house of pain.
KMI: 38.57 (-0.18), MU: 32.99 (-0.02), LMT: 186.81 (+0.66), SWKS: 61.19 (+1.31), OPK: 8.58 (+0.26), TXN: 51.51 (+0.61), QCOM: 69.91 (+0.65), BPL: 79.62 (+0.32), AVAV: 29.12 (-0.69), IRM: 37.45 (-0.60), SNE: 20.53 (+0.91), SDRL: 21.85 (+0.08)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.63 (+0.50), KMI: 38.57 (-0.18), HK: 3.23 (-0.01), KSS: 56.86 (-0.36), GE: 26.47 (+0.06), LMT: 186.81 (+0.66), AVAV: 29.12 (-0.69), WMT: 80.05 (+1.28), SNE: 20.53 (+0.91), M: 59.58 (-0.30), SDRL: 21.85 (+0.08), T: 35.08 (+0.17), W: 26.43 (+0.42), OPK: 8.58 (+0.26), QCOM: 69.91 (+0.65), TWTR: 40.03 (-0.28), EPR: 57.59 (+0.98), AAPL: 108.98 (-0.03), HSIC: 129.36 (+0.52), CSCO: 25.20 (-0.13), WFM: 47.80 (+0.99), CY: 10.17 (+0.09), MU: 32.99 (-0.02), SWKS: 61.19 (+1.31), IRM: 37.45 (-0.60), BAC: 17.35 (-0.01), MO: 49.98 (+0.11), CSX: 36.38 (+0.93), WWAV: 35.80 (-1.13), GILD: 107.18 (+0.73), TXN: 51.51 (+0.61), BPL: 79.62 (+0.32), JCP: 7.37 (-0.45), JWN: 72.46 (-0.97), BABA: 117.47 (+2.91)
OPKO To Hold Conference Call on November 10, 2014
Business Wire - Fri Nov 07, 10:31AM CST
OPKO Health, Inc. (NYSE:OPK) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014, before the market opens. OPKO's senior management team will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, November 10, 2014 to discuss the Company's results in greater detail.
OPK: 8.58 (+0.26)
OPKO Health misses 3Q revenue forecasts
Automated Insights - Fri Nov 07, 7:45AM CST
MIAMI (AP) _ Opko Health Inc. (OPK) on Friday reported a loss of $48.7 million, or 11 cents per share, in its third quarter.
OPK: 8.58 (+0.26)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.22 (+0.06), OPK: 8.58 (+0.26), VNDA: 12.04 (+0.25), MDXG: 10.01 (-0.23), PDLI: 7.79 (-0.19)
OPKO Announces Third Quarter Operating and Financial Results
Business Wire - Fri Nov 07, 7:28AM CST
--Rayaldee Results to be Presented at American Society of Nephrologists Meeting
OPK: 8.58 (+0.26)
DSG and OPKO Health Enter into Enterprise Licensing Agreement for Fully Integrated EDC, IWRS, Safety, and Trial Management Solution
Business Wire - Tue Nov 04, 9:14AM CST
OPKO Health, Inc., a multinational pharmaceutical & diagnostics company, has selected DSG's eCaseLink integrated suite for self-building of harmonized electronic data capture (EDC), IWRS, drug safety event capture and case reporting, and CTMS systems. DSG's team will support the OPKO team and their Site users 24 x 365.
OPK: 8.58 (+0.26)
Insider Trading Recap for Alpha Pro Tech, Opko Health, Yelp, Glu Mobile, Lakeland Industries, and Plug Power
PR Newswire - Fri Oct 31, 7:45AM CDT
Insiderslab.com, an US market research community has a special focus on updating investors with insider trading news, reveals the latest insider trading alerts for the US stock investors, who can access these reports through the links below, including stock performance, insider trading signals, and visual results. The reports cover the stocks of Alpha Pro Tech (NYSEMKT:APT), Opko Health (NYSE:OPK), Yelp (NYSE:YELP), Glu Mobile (NASDAQ:GLUU), Lakeland Industries (NASDAQ:LAKE), and Plug Power (NASDAQ
LUG). OPK: 8.58 (+0.26), PLUG: 5.24 (-0.06), APT: 3.26 (unch), LAKE: 13.18 (-0.11), GLUU: 3.77 (+0.06), YELP: 59.16 (+0.75)
5 Stocks Insiders Love Right Now
at The Street - Wed Oct 29, 12:00PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
AGO: 24.71 (+0.18), OPK: 8.58 (+0.26), JONE: 13.15 (-0.39), SHLD: 39.62 (-3.19), SLB: 98.93 (+0.20)
Investments Gamma. Frost Trust of Opko Health, Inc. (OPK)-NYSE bought Shares of OPK
M2 - Fri Oct 24, 7:57AM CDT
Reported by InsiderCow.com at 2014-10-23 08:00:05 ET
OPK: 8.58 (+0.26)
Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 8.58 (+0.26)
Critical Alerts For Boston Beer, Apollo Group, Opko Health, Vale and Silver Wheaton Released By InvestorsObserver
PR Newswire - Mon Oct 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SAM, APOL, OPK, VALE and SLW.
OPK: 8.58 (+0.26), VALE: 9.20 (-0.23), SLW: 18.11 (-0.75), SAM: 264.07 (+5.17), APOL: 28.98 (-0.46)
'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin
at The Street - Thu Oct 16, 5:00AM CDT
Cramer says be careful about Compressco Partners, buy RPM International and consider Rite Aid a great long-term story.
LMT: 186.81 (+0.66), LEN: 45.72 (+1.18), OPK: 8.58 (+0.26), GWPH: 73.33 (-0.64), RPM: 46.51 (+0.10), GSJK: 22.74 (-0.42), RAD: 5.49 (+0.08)
Jim Cramer's 'Mad Money' Recap: More Nails in the Market's Coffin
at The Street - Wed Oct 15, 7:28PM CDT
The markets will continue to be driven by news, with stocks being guilty until proven innocent, Cramer warns.
LMT: 186.81 (+0.66), LEN: 45.72 (+1.18), CLR: 55.69 (+0.56), OPK: 8.58 (+0.26), GWPH: 73.33 (-0.64), SHPG: 200.52 (+1.94), LNG: 72.46 (+0.51), WMT: 80.05 (+1.28), RPM: 46.51 (+0.10), FRT: 134.26 (+1.36), ABBV: 63.54 (+2.04), GSJK: 22.74 (-0.42), RAD: 5.49 (+0.08), CRM: 64.12 (+0.15)
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A Multinational, Multicenter Early Feasibility Trial of the Tiara(TM) Transcatheter Mitral Valve
Business Wire - Thu Oct 09, 10:15AM CDT
OPKO Health, Inc. (NYSE:OPK) announced that its investee, Neovasc, has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara(TM) transcatheter mitral valve. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted to assess the safety and performance of Neovasc's Tiara mitral valve system and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).
OPK: 8.58 (+0.26)
Masimo Gets CE Mark Approval for 11th Rainbow Parameter - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 12:50PM CDT
Masimo Corporation's (MASI) Oxygen Reserve Index (ORI) is the first non-invasive and continuous parameter of its kind which provides an insight into patients' oxygen reserve when they are receiving supplemental oxygen.
GE: 26.47 (+0.06), MASI: 25.60 (+0.08), OPK: 8.58 (+0.26), ERB: 2.75 (-0.37)
Mazor Robotics Ltd. (MZOR) in Focus: Stock Soars 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 8:18AM CDT
Mazor Robotics Ltd. (MZOR) was a big mover last session, as the company saw its shares rise by over 11% on the day.
OPK: 8.58 (+0.26), MZOR: 10.43 (-0.51), ERB: 2.75 (-0.37)
Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences
PR Newswire - Tue Sep 30, 7:50AM CDT
Investor-Edge has initiated coverage on the following equities: Immunomedics Inc. (NASDAQ: IMMU), Aeterna Zentaris Inc. (NASDAQ: AEZS), OPKO Health Inc. (NYSE: OPK), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, September 29, 2014, the NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow Jones Industrial Average finished the day 0.25% lower at 17,071.22, and the S&P 500 closed at 1,977.80, down 0.25%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 744.38, down 0.18%, while the index has advanced 0.92% in the last one month. Register for your complimentary reports on these five stocks at:
IMMU: 3.66 (+0.05), NAVB: 1.04 (-0.18), OPK: 8.58 (+0.26), AEZS: 0.59 (+0.02), EXAS: 22.34 (-0.48)
